Literature DB >> 12593623

Growth pattern and rate in residual nonfunctioning pituitary adenomas: correlations among tumor volume doubling time, patient age, and MIB-1 index.

Yuichiro Tanaka1, Kazuhiro Hongo, Tsuyoshi Tada, Keiichi Sakai, Yukinari Kakizawa, Shigeaki Kobayashi.   

Abstract

OBJECT: Surgical cure can be achieved in pituitary adenomas when they are completely removed. It is controversial whether postoperative radiation therapy should be given to prevent recurrence, and whether an early reoperation should be performed for residual adenomas, because we have little information about the natural history of postoperative residual adenomas.
METHODS: The residual tumor volume was serially measured in 40 nonfunctioning pituitary adenomas (NFPAs) and the tumor volume doubling time (TVDT) was calculated. Correlations between the patients' age, tumor volume, log TVDT, and MIB-1 index were examined. Other factors including the patient's sex, cavernous sinus (CS) invasion by the tumor, or presence of an intratumoral cyst were analyzed to assess their influence on the TVDT. Values are expressed as the means +/- standard deviations. Thirty-eight adenomas increased in volume and two decreased during a follow-up period ranging from 4 to 141 months (mean 52.5 months). Exponentially linear tumor growth was observed in the 38 growing adenomas regardless of the residual tumor volume, with the TVDT ranging from 506 to 5378 days (mean 1836 days). The patients' age was 57.1 +/- 15.7 years (range 15-79 years), the tumor volume at the beginning of the magnetic resonance imaging observation period was 2.5 +/- 2.2 cm3 (range 0.07-14.5 cm3), and the MIB-1 index was 0.73 +/- 0.68% (range 0.1-2.9%). There was a correlation between the log TVDT and patient age (R = 0.73), an inverse correlation between the log TVDT and MIB-1 index (r = -0.49), and an inverse correlation between the MIB-1 index and patient age (r = -0.61). A significant difference (p = 0.0001) was noted between the TVDT (1,106 days) in the 19 patients younger than 61 years of age and the TVDT (2566 days) in the 19 patients who were 61 years of age or older. There was also a significant difference (p = 0.0002) between the age (50.8 +/- 15.3 years) of the patients with rapidly growing tumors (TVDT < 1,836 days, 24 patients) and the age (69.1 +/- 7.6 years) of the patients with slowly growing tumors (TVDT> 1836 days, 14 patients). Other factors including the patients' sex, CS invasion, and intratumoral cyst formation did not affect the TVDT of residual NFPAs.
CONCLUSIONS: The tumor growth rate of residual NFPAs is strongly influenced by the patient's age. The TVDT in elderly patients is much longer than that previously reported. Treatment strategies that take into consideration the natural history of residual adenomas should be established especially in the elderly population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12593623     DOI: 10.3171/jns.2003.98.2.0359

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  26 in total

1.  The clinical significance of MIB-1 labeling index in pituitary adenomas.

Authors:  Geeta Chacko; Ari G Chacko; Kalman Kovacs; Bernd W Scheithauer; Sunithi Mani; J P Muliyil; M S Seshadri
Journal:  Pituitary       Date:  2010-12       Impact factor: 4.107

2.  Determination of cell proliferation using Mcm2 antigen and evaluation of apoptosis and TGF-beta1 expression in GH-secreting or clinically nonfunctioning pituitary adenomas.

Authors:  Cristina Micheletto Dallago; Ligia Maria Barbosa-Coutinho; Nelson Pires Ferreira; Rosalva Meurer; Julia Fernanda Semmelmann Pereira-Lima; Miriam da Costa Oliveira
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

Review 3.  Is there a role for early chemotherapy in the management of pituitary adenomas?

Authors:  Andrew L Lin; Melissa W Sum; Lisa M DeAngelis
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

Review 4.  Prognostic factors of regrowth in nonfunctioning pituitary tumors.

Authors:  Gerald Raverot; Alexandre Vasiljevic; Emmanuel Jouanneau
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

Review 5.  Clinical Impact of the Current WHO Classification of Pituitary Adenomas.

Authors:  W Saeger; J Honegger; M Theodoropoulou; U J Knappe; C Schöfl; S Petersenn; R Buslei
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

6.  Early postoperative growth in non-functioning pituitary adenomas; A tool to tailor safe follow-up.

Authors:  Kristin Astrid Øystese; Manuela Zucknick; Olivera Casar-Borota; Geir Ringstad; Jens Bollerslev
Journal:  Endocrine       Date:  2017-05-17       Impact factor: 3.633

Review 7.  Radiotherapy of nonfunctioning and gonadotroph adenomas.

Authors:  Andrew A Kanner; Benjamin W Corn; Yona Greenman
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

8.  Transcranial approach to pituitary adenomas invading the cavernous sinus: A modification of the classical technique to be used in a low-technology environment.

Authors:  Aldo Spallone; Roberto V Vidal; Justo G Gonzales
Journal:  Surg Neurol Int       Date:  2010-07-01

9.  Retrospective observational analysis of non-irradiated non-functioning pituitary adenomas.

Authors:  I Karamouzis; R Berardelli; N Prencipe; A Berton; C Bona; G Stura; M Corsico; V Gasco; M Maccario; E Ghigo; S Grottoli
Journal:  J Endocrinol Invest       Date:  2015-07-28       Impact factor: 4.256

10.  The role of the le fort I maxillotomy in the management of incompletely resected pituitary macroadenomas.

Authors:  Bruce Mickey; Leslie Hutchins; Edward Ellis
Journal:  Skull Base       Date:  2007-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.